文献速递炎症性肠病

维得利珠单抗治疗炎症性肠病的一年有效性与安全性:一项前瞻性多中心队列研究

One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-06-08

该前瞻性多中心队列研究纳入2014年6月至12月接受维得利珠单抗诱导治疗的173例克罗恩病(CD)和121例溃疡性结肠炎(UC)患者,272例完成诱导期并于第14周评估。第54周无激素临床缓解率CD为27.2%、UC为40.5%,持续无激素临床缓解率分别为8.1%和19.0%,未观察到死亡,严重不良事件17例(7.2%)。

要点

  • 第54周无激素临床缓解率:CD 27.2%,UC 40.5%。
  • 第14周至第54周持续无激素临床缓解率:CD 8.1%,UC 19.0%。
  • 严重不良事件17例(7.2%),其中6例(2.5%)导致停药,无死亡。

核心结论

  • 维得利珠单抗能在第54周使至多三分之一的UC和CD患者维持无激素临床缓解,安全性尚可。
  • 相当比例患者在治疗第一年内出现应答丢失,尤其是CD患者。

研究设计与样本

  • 前瞻性多中心队列研究,2014年6月至12月接受维得利珠单抗诱导治疗的173例CD和121例UC患者,共294例。
  • 272例完成诱导期并于第14周评估(CD 161例,UC 111例)。
  • 疾病活动度采用Harvey-Bradshaw指数(CD)和部分Mayo临床评分(UC)评估。
  • 主要结局为第54周无激素临床缓解。

主要发现

  • 第54周无激素临床缓解率CD为27.2%,UC为40.5%。
  • 第14周至第54周持续无激素临床缓解率CD为8.1%,UC为19.0%。
  • 未观察到死亡。
  • 严重不良事件发生于17例(7.2%)患者,其中6例(2.5%)导致维得利珠单抗停药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. AIMS: To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. METHODS: Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with vedolizumab induction therapy. Among those 294 patients, 272 completed the induction period and were evaluated at the week 14 visit (161 patients with CD and 111 with UC). Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. The primary outcome was steroid-free clinical remission at week 54. RESULTS: At week 54, steroid-free clinical remission rates at week 54 were 27.2% and 40.5% in patients with CD and UC respectively. In addition, the sustained steroid-free clinical remission (from week 14 to week 54) rates were 8.1% and 19.0% respectively. No deaths were observed. Severe adverse events occurred in 17 (7.2%) patients, including six (2.5%) leading to vedolizumab discontinuation. CONCLUSION: Vedolizumab is able to maintain steroid-free clinical remission in up to one-third of patients with UC and CD at week 54 with a reasonable safety profile. A significant number of patients experienced loss of response during the first year of treatment, particularly in patients with CD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017. PMID: 28593685. doi:10.1111/apt.14167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。